CYTOKINE IMMUNITYINCKD PATIENTS TREATED WITH HD, HDF, PD

  • V.E. Dryanska SI «Institute of Nephrology NAMS of Ukraine»
  • I.O. Dudar SI «Institute of Nephrology NAMS of Ukraine»
  • I. Shifris SI «Institute of Nephrology NAMS of Ukraine»
  • Yu.I. Gonchar SI «Institute of Nephrology NAMS of Ukraine»
  • O.M. Loboda SI «Institute of Nephrology NAMS of Ukraine»
  • F.Z. Galsenluk SI «Institute of Nephrology NAMS of Ukraine»
  • V.F. Krot SI «Institute of Nephrology NAMS of Ukraine»
Keywords: chronic kidney disease Vstage, pro-inflammatory cytokines, renal replacement therapy.

Abstract

Introduction. Cytokines play the corresponding role in the inflammatory processes and the development of endothelial dysfunction and therefore take an important place in the problem of systemic chronic inflammation (SCI) in patients with chronic kidney disease (CKD), stage V, who are treated with methods of the renal replacement therapy (RRT).

Aim of the work was to determine the features ofpro- and anti-inflammatory cytokines, VEGF in patients with CKD stage V D, depending on the method of RRT (HD, HDF, PD).

Materials and methods. There were examined 56 patients with CKD, st. V treated with methods of RRT: gr.1 received hemodialysis (HD) (15 p), gr. 2 - hemodiafiltration (HDF) (28 p) and gr. 3 – peritoneal dialysis (PD) (13p). The cytokines levels (IL-6, -8, -10, -18, TNF-a, VEGF) were determined in blood serum by means of ELIZA.

Results. The CKD, st. V patients treated with RRT showed really increased levels of pro-inflammatory blood cytokines (TNF-a, IL-8, IL-18) (p < 0.001) and VEGF as important factor of endothelial dysfunction, in dependence on RRT the groups 1-3 did not differ (p > 0.05). In comparison with healthy donors, in patients of gr. 3 the level of antiinflammatory IL-10 was the highest (p < 0.001) in comparison with gr.1 (p = 0.080) andgr.2 (p = 0,043) (corresponding HD and HDF), and the ratio IL-18/IL-10 was really more low in comparison with both other groups (p = 0.035).

Conclusion. The high level of serum cytokines confirms the SCI availability in patients with CKD,st.V; the patients treated with PD showed the lower degree of inflammatory reactions by the data of balance between pro/anti-inflammatory immunity mediators.

Downloads

Download data is not yet available.

References

Гусев Е. Ю. Хроническое системное воспаление как типовый патологический процесс / Е. Ю. Гусев, Л. Н. Юрченко, В. А. Черешнев, Ю. А. Журавлева, Л. В. Соломатина // Цитокины и воспаление. – 2008. – Т. 7, № 4. – С. 3-10.

Дріянська В. Є. Прозапальні цитокіни (ІЛ-1Д ФНП-а) та оксидантно-антиоксидантний баланс крові хворих на хронічну хворобу нирок V Д стадії з різним станом коморбідності /

B. Є. Дріянська, Л. В. Король, І. О. Дудар [та ін.] // Імунологія та алергологія. Наука і практика. - 2014 - № 1 - С. 25-30.

Семенов В. Н. Апоптоз и его роль в патогенезе критических состояний / В. Н. Семенов, И. Н. Пасечник // Вестн. интенсивн. тер. – 2004. – № 1. – С. 3-7.

Синяченко О. В. Ремоделирование тубулоин- терстиция и роль нефропротекции в прогрес - сировании хронических гломерулонефритов / О. В. Синяченко, Г. А. Игнатенко, И. В. Мухин // Нефрология. – 2006. - № 1. – С. 99-102.

Татарко С. В. Імунологічні механізми хроніза- ції запалення : автор. ... д. мед. наук : 14.03.04 / C. В. Татарко. – Харків, 2011. – 35 с.

Фрейдлин И. С. Регуляторные Т-клетки: Происхождение и функции / И. С. Фрейдлин // Мед. иммунология. – 2005. – Т. 7, № 4. – С. 347-354.

Akhurst R. Targeting the TGFbeta signaling pathway in disease / R. Akhurst, A. Hata // Nat Rev Drug Discov. – Vol. 11. – 2012. – P. 790-811.

Charles A. D. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process / F. D. Charles // American Journal of Clinical Nutrition – 2006. - Vol. 83, No. 2. – P. 447S - 455S.

Chaudhry A. Occurrence of pyuria and bacte- riuria in asymptomatic hemodialysis patients / A. Chaudhry, W. J. Stone, J. A. Breyer // Am J Kidney Dis. - 1993. - 21. - Р. 180-183.

Cooke A. Th17 Cells in Inflammatory Conditions / A. Cooke // Rev. Diabet. Stud. – 2006. – No. 3 (2). - Р. 72-75.

Halwani R. Role of transforming growth factor-beta in airway remodeling in asthma / R. Halwani, S. Al- Muhsen, H. Al-Jahdali,Q. Hamid // Am.J.Respir Cell.Mol.Biol. - Vol. 44. - 2011. - P. 127-133.

Klahr S. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease / S. Klahr, J. M. Jeremiah // Kidney Int.- 2000. - Suppl. 75. - P.7-14.

Ostalska-Nowicka D. Vascular endothelial growth factor (VEGF-C1)-dependent inflammatory response of podocytes in nephrotic syndrome glomerulopathies in children: an immunohistochemical approach / D. Ostalska-Nowicka [et al.] // Histopathology. - 2007. - 46 (2). - Р. 176-183.

Rao M. Cytokine gene polymorphism and progression of renal and cardiovascular diseases / M. Rao [et al.] // Kidney International. - 2007. - 72. - Р. 549-556.

Sugama S. Interleukin-18 and stress. Brain research reviews / S. Sugama 2008. - Vol. 58, No 1. - P. 85 - 95.

Watanabe T. Is vascular endothelial cell growth factor (VEGF) involved in the pathogenesis of diabetic nephropathy ? / T. Watanabe // Nephrology. - 2007. - Vol. 12. - P. S27-S27.

Wasilewska A. Glucocorticoid receptor and vascular endothelial growth factor in nephrotic syndrome / A. Wasilewska, W. Zoch-Zwierz // Acta Paediatrica. - 2006. - Vol. 95, Issue 5. - P. 587-593.

Yang Y. Transforming growth factor в pathways in inflammatory airway diseases / Y. Yang, N. Zhang, F. Lan [et al.] // Allergy. - 2014. - Vol. 69, N 6. - P. 699-707.


Abstract views: 345
PDF Downloads: 202
Published
2016-12-12
How to Cite
Dryanska, V., Dudar, I., Shifris, I., Gonchar, Y., Loboda, O., Galsenluk, F., & Krot, V. (2016). CYTOKINE IMMUNITYINCKD PATIENTS TREATED WITH HD, HDF, PD. Ukrainian Journal of Nephrology and Dialysis, (4(52), 47-51. https://doi.org/10.31450/ukrjnd.4(52).2016.03

Most read articles by the same author(s)

1 2 > >>